- Deep sleep drives growth hormone release, not the reverse (Cordi et al., Communications Biology, 2022).
- No sleep-lab study of ipamorelin exists. GHRP-2, which acts on the same receptor, produced no increase in deep sleep in a 1998 human sleep-lab trial (Copinschi et al.).
- Ghrelin, the natural hormone for that receptor, did increase deep sleep in a 2003 human study (Weikel et al.). The GHRH pathway has more replicated human sleep evidence.
- Three genes have been linked to how deep and how late people sleep: ADA (adenosine clearance), PER3 (sleep pressure) and CLOCK (timing). None has been studied with ipamorelin.
- Ipamorelin is not FDA-approved and may not be compounded by US pharmacies under 503A. It is prohibited in sport.
A common claim is that ipamorelin raises growth hormone, and growth hormone improves sleep. A 2022 study in Communications Biology suggests the relationship runs the other way: deep sleep drives the growth hormone pulse. This page sets out what sleep research has shown about that link, what has and has not been tested for ipamorelin and its relatives, and what the genetics of sleep depth and timing do and do not say. It is not a guide to using ipamorelin, which is not an approved medicine.
Roughly 75% of a day's growth hormone output is tied to the first stretch of deep (slow-wave) sleep of the night, per Van Cauter and Plat, Journal of Clinical Endocrinology and Metabolism, 1996.
Growth hormone is released in pulses, and the biggest one of the day comes early in the night, locked to the start of deep sleep. Research now shows the sleep comes first and the hormone follows.
Why "ipamorelin raises growth hormone, which improves sleep" gets the direction wrong
In 2022, Cordi and colleagues tested which way the relationship runs. They blocked growth hormone during sleep with a drug, and deep sleep did not change. Then they deepened sleep with sound played at the right moment during deep sleep, and growth hormone release went up. Deep sleep drives the hormone.
"Slow-wave sleep enhancement significantly increased GH secretion, whereas GH receptor blockade did not alter slow-wave sleep. This indicates that SWS drives GH release rather than the reverse."
Cordi et al., Communications Biology, 2022
This built on older work. Takahashi and colleagues showed in Science (1968) that the big overnight growth hormone pulse is locked to the start of deep sleep, and Van Cauter and Plat (1996) showed that depriving people of deep sleep blunts and delays it. Cordi 2022 established direction by intervening rather than observing.
The sleep-lab results for this class of compounds
Ipamorelin acts on the ghrelin receptor (GHSR) in the pituitary and hypothalamus and triggers a growth hormone pulse without meaningfully raising cortisol or prolactin, per its 1998 human pharmacology study.
Copinschi and colleagues (1998, American Journal of Physiology-Endocrinology and Metabolism) studied GHRP-2, which acts on the same receptor, in healthy men in a sleep lab. It had no effect on deep sleep, with a slight, non-significant trend toward more wakefulness in the first hour. GHRP-6 increased light sleep but changed neither deep sleep nor dreaming sleep. Ghrelin itself did increase deep sleep in a 2003 study by Weikel and colleagues (American Journal of Physiology), mainly in the first two thirds of the night.
No sleep-lab study of ipamorelin itself exists in the indexed literature. Sleep claims for it are extrapolated from the ghrelin result and from growth hormone biology.
Several replicated human studies, reviewed by Steiger and by Antonijevic, show GHRH deepens sleep, raises growth hormone and lowers cortisol.
Ghrelin deepened sleep in humans (Weikel 2003). GHRP-2 showed no deep-sleep effect (Copinschi 1998). Ipamorelin has not been tested in a sleep lab.
For how the two receptor routes differ, see ipamorelin vs CJC-1295.
Three genes linked to how deep and how late people sleep
None of these genes has been studied with ipamorelin or any other peptide. What research establishes is how they relate to sleep itself.
1. ADA: how fast adenosine is cleared
Adenosine builds up in the brain during waking hours and creates pressure to sleep; deep sleep is when it is cleared. ADA is the enzyme that breaks it down, and a common variant (rs73598374, G22A) makes the enzyme slower. Bachmann and colleagues (2012, Cerebral Cortex) found carriers had more deep-sleep activity on EEG, fewer awakenings and higher sleep efficiency. A replication in about 800 people (EPISONO cohort, PLOS ONE, 2012) confirmed the deep-sleep finding.
2. PER3: how strongly sleep pressure builds
PER3 contains a stretch of DNA that repeats four or five times. Roughly one in ten people of European ancestry carry two five-repeat copies. Viola and Dijk (2007, Current Biology) found these people built sleep pressure faster and showed more deep-sleep activity, and Groeger and colleagues (2009, PLOS ONE) found they were more impaired by short nights.
3. CLOCK: when the body clock runs
CLOCK rs1801260 (T3111C) is a well-characterised genetic association with evening preference. Carriers have been reported to release melatonin later and fall asleep later. A 2024 review in Trends in Genetics covers the association with delayed sleep phase across several cohorts.
These are associations with sleep traits in populations. They do not predict how anyone would respond to a peptide, and no study has tested that.
What is ipamorelin's status in 2026?
Ipamorelin is not FDA-approved. In September 2023 the FDA placed it in Category 2 of the interim 503A bulks list, which blocked compounding; the nomination was withdrawn in September 2024, which did not authorise compounding. The FDA's Pharmacy Compounding Advisory Committee voted against recommending it for the 503A bulks list in October 2024, and it is not on that list today, so US pharmacies may not compound it. It is prohibited at all times in sport. For the wider picture, see peptide regulatory status in the US in 2026.
The short version: deep sleep drives growth hormone, not the reverse. Ipamorelin has never been tested in a sleep lab, and its closest relative showed no deep-sleep effect. Genes such as ADA, PER3 and CLOCK shape how deep and how late people sleep, but none has been studied with any peptide. If you want to see which sleep-related variants you carry and what the research on each does and does not show, your report reads the DNA file you already have against the published research. More is on the ipamorelin reference page.
Watch
What clinicians and researchers say about Ipamorelin
1 hr 30 minPeptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex TatemThe Diary of a CEO · PodcastBPC-157TB-500MOTS-c
13 minDr. Explains Peptide Stacks Used for Muscle GrowthAshley Froese · EducatorSermorelinCJC-1295Tesamorelin
19 minLearn Peptides So Fast it's UNREALAshley Froese · EducatorGHK-CuKPVThymosin Alpha-1Frequently asked questions
Does ipamorelin improve sleep?
It has not been tested. No sleep-lab study of ipamorelin exists. GHRP-2, which acts on the same receptor, produced no change in deep sleep in a 1998 sleep-lab trial (Copinschi et al.), while ghrelin itself increased deep sleep in a 2003 study (Weikel et al.). Claims for ipamorelin are extrapolations from that work.
Does growth hormone improve sleep, or does sleep raise growth hormone?
Sleep raises growth hormone. In Cordi et al. (Communications Biology, 2022), blocking growth hormone did not change deep sleep, while deepening sleep with timed sound increased growth hormone release. The big overnight pulse is locked to the start of deep sleep.
Which genes affect deep sleep?
Three well-studied examples are ADA rs73598374 (linked to more deep-sleep activity in Bachmann et al. 2012), the PER3 five-repeat variant (faster build-up of sleep pressure in Viola and Dijk 2007) and CLOCK rs1801260 (associated with later sleep timing). None has been studied with any peptide.
Does the GHRH pathway affect sleep?
Yes, in human studies. Several replicated studies, reviewed by Steiger and by Antonijevic, found that GHRH deepens sleep, raises growth hormone and lowers cortisol. That evidence concerns GHRH itself, not any specific compound sold as a peptide.
Is ipamorelin FDA-approved?
No. It is not FDA-approved, it is not on the 503A bulks list, and the FDA's compounding advisory committee voted against recommending it in October 2024, so US pharmacies may not compound it. It is prohibited at all times in sport.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.